Phil has over 40 years’ experience in preclinical safety assessment in a contract research environment primarily focused in toxicology and pharmacology. With experience in CNS and cardiovascular pharmacology, Phil played a role in establishing one of the first laboratories in the world to offer safety pharmacology. He spent nearly 20 years with the Department of Pharmacology at Huntingdon Research Center in the UK before joining Quintiles Inc; where he was the Executive Director of Safety Pharmacology and later Senior Director of Pharmacology and Discovery Services at WIL Research. Phil joins Charles River with the acquisition of Citoxlab (formerly Xenometrics). He holds a BSc and MSc from the University of East London in the UK.
Phil Atterson, BS, MSc